NCT02596256

Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)

Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Chinese PLA General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer.

Detailed description

This trial investigated the safety and efficacy of apatinib plus docetaxel, as a treatment option for heavily pretreated patients with advanced gastric cancer.

Conditions

• Gastric Cancer

Interventions

Type	Name	Description
DRUG	Apatinib	Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
DRUG	Docetaxel	Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity

Timeline

• Start date: 2016-04-01
• Primary completion: 2019-02-01
• Completion: 2019-02-01
• First posted: 2015-11-04
• Last updated: 2018-04-17

Locations

1 site across 1 country: China